Neurogene Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparisons are with FY2022. Neurogene is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. The December 18, 2023 reverse merger brought Neurogene’s business into the public company, formerly Neoleukin Therapeutics, Inc.; results and per-share data span pre- and post-merger periods and are not fully comparable.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $44.4 million | $47.5 million |
| General and administrative expense | $11.2 million | $9.0 million |
| Total operating expenses | $55.6 million | $56.5 million |
| Net loss | $36.3 million | $55.2 million |
| Net cash used in operating activities | $51.4 million | $52.8 million |
The FY2023 net loss included a $16.4 million non-cash bargain purchase gain from the reverse merger; absent product revenue, the company remains loss-making. FY2023 research and development spending decreased by $3.1 million, while G&A increased by $2.2 million. Interest income rose to $3.0 million from $1.3 million.
At year-end, cash and cash equivalents were $148.2 million and short-term U.S. Treasury investments were $48.9 million, totaling $197.2 million. Management estimates current resources will fund operations into the second half of 2026, subject to assumptions; it also states resources are sufficient for at least 12 months after issuance of the financial statements. FY2023 financing cash flow included $92.3 million net proceeds from the pre-closing financing. The filing reports no product sales or meaningful near-term revenue expectation.
No conventional borrowings are reported. Lease liabilities were $14.9 million operating and $0.1 million finance at year-end; undiscounted future operating lease payments totaled $18.6 million. The company expects substantial additional capital needs and warns that future equity financing could dilute shareholders. Profit margins are not meaningful because the company has no product revenue.
Business and development updates
- NGN-401 (Rett syndrome): Phase 1/2 open-label trial of one-time intracerebroventricular dosing. Three patients had been dosed in the low-dose cohort by the filing; the company reported no treatment-emergent or procedure-related serious adverse events or signs of overexpression toxicity in those patients. In February 2024, the protocol was amended to expand the low-dose cohort to eight patients and add an eight-patient high-dose cohort. Interim low-dose data were targeted for Q4 2024, with additional data, including high-dose data, targeted for the second half of 2025.
- NGN-101 (CLN5 Batten disease): Phase 1/2 trial using intracerebroventricular and intravitreal administration. The first two dosing cohorts were enrolled; enrollment in a higher-dose cohort was underway. Interim data were expected in the second half of 2024. The company planned to seek an FDA meeting in the second half of 2024 on clinical requirements and a potential streamlined registration path.
- The EXACT transgene-regulation platform is being developed to control gene expression. The company also reported multiple discovery programs and expected to advance one into clinical development in 2025. These timelines are forward-looking and depend on clinical, regulatory, and manufacturing progress.
Material changes, unusual items, and risks
- The reverse merger closed December 18, 2023, with a 1-for-4 reverse stock split. Neurogene raised approximately $95.0 million gross in pre-closing financing; reported net financing proceeds were $92.3 million. The transaction generated the $16.4 million bargain purchase gain.
- Legacy Neoleukin assets and lease obligations are subject to contingent value rights for former Neoleukin holders. The company recorded a $1.3 million lease-CVR liability; other potential CVR proceeds or payments were not considered probable and estimable at year-end. The company is seeking a subtenant for 33,300 square feet of Seattle space, and net proceeds from certain legacy asset dispositions or lease savings may go to CVR holders.
- An August 2023 business email compromise diverted approximately $0.9 million to fraudulent accounts. The company reported recovery of $0.7 million by year-end and a further $0.2 million after year-end. The incident exposed a material weakness in controls over supplier payment changes; management said it was remediated as of December 31, 2023. The auditor did not provide an attestation on internal-control effectiveness.
- Key risks include clinical failure or safety issues, uncertain regulatory pathways for gene therapies, small and difficult-to-enroll patient populations, manufacturing scale-up and supply constraints, dependence on the University of Edinburgh collaboration, and the need for additional capital. Preclinical NGN-401 studies observed transient liver-enzyme elevations and mild-to-slight nervous-system findings; these are not proof of human safety. Rare pediatric disease priority-voucher eligibility is uncertain and depends on statutory program timing.
- The company reported no legal proceedings expected to have a material adverse effect. Its financial statements received an unqualified audit opinion.
Most important facts for investors to verify
- Whether NGN-401 and NGN-101 clinical updates meet the stated timing and demonstrate meaningful safety and efficacy, including longer-term follow-up.
- Actual cash burn and runway as trial enrollment, manufacturing, and other development spending increase; the runway estimate depends on management assumptions.
- Whether additional financing is needed and its potential dilution or other terms.
- Manufacturing readiness, clinical supply availability, and FDA alignment on future trial and registration requirements.
- Progress in subleasing or otherwise addressing legacy Seattle leases, and the resulting CVR liabilities or proceeds for eligible former holders.
- Whether the cybersecurity and financial-control remediation remains effective and whether further amounts from the diverted funds are recovered.